Masimo Taps Katie Szyman
After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...
Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.
Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointe ...
MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.
Looking ahead to 2025, Masimo projects healthcare revenues to land between $1.5 billion and $1.53 billion. That would deliver ...
Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback